A Phase IV, Open Label, Study Evaluating the Safety and Efficacy of Polatuzumab Vedotin in Combination With Rituximab and CHP (R-CHP) in Previously Untreated Adult Patients With Diffuse Large B-Cell Lymphoma (DLBCL) – RGCI, DELHI
| Protocol Id | PI | Protocol Title | INDICATION | PHASE | Sponsor | CRO/ Other |
| D7401C00001 | Dr. Dinesh Bhurani | A Phase III, Multicentre, Randomised, Open-label Study to Compare the Efficacy and Safety of AZD0486 plus Rituximab versus Chemotherapy plus Rituximab in Previously Untreated Participants with Follicular Lymphoma (SOUNDTRACK-F1). | FL | III | Astrazeneca | N/A UPCOMING RGCI |
| Protocol Id | PI | Protocol Title | INDICATION | PHASE | Sponsor | CRO/ Other |
| BREN.24.001 | Dr. Dinesh Bhurani | A prospective, randomized, multicenter, comparative, double-blind, parallel group study to evaluate the efficacy, safety, pharmacokinetics, and immunogenicity of test brentuximab vedotin (ZRC-3318) with reference brentuximab vedotin (Adcetris®), in combination with chemotherapy, in patients with previously untreated stage III or IV classical Hodgkin lymphoma | CHL | III | Zydus | N/A |
| APG2575CG301 | Dr. Dinesh Bhurani | A Global Multicenter, Open Label, Randomized Phase 3 Registrational Study of Lisaftoclax (APG-2575) in Previously Treated Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma(GLORA) | CLL/SLL | III | Ascentage | IQVIA |
| APG2575CC301 | Dr. Dinesh Bhurani | A Global Multicenter, Open Label, Randomized Phase III Confirmatory Study of Lisaftoclax (APG-2575) in Combination with Acalabrutinib versus Immunochemotherapy in Patients with Newly Diagnosed Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (GLORA-2 Study) | CLL/SLL | III | Ascentage | IQVIA |
| GPL ZANU-401 | Dr. Dinesh Bhurani | An Open Label, Phase IV, Single Arm, Multicentric,Prospective Study to evaluate the safety and efficacy of Zanubrutinib in Patients with B-Cell Lymphomas (ZAP-BCL) | B-Cell Lymphoma | IV | Innovate Research | N/A |